;PMID: 9856847
;source_file_1379.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..42] = [t:0..42]
;1)sentence:[e:47..210] = [t:47..210]
;2)section:[e:214..262] = [t:214..262]
;3)section:[e:266..339] = [t:266..339]
;4)sentence:[e:343..715] = [t:343..715]
;5)sentence:[e:716..816] = [t:716..816]
;6)sentence:[e:817..1065] = [t:817..1065]
;7)sentence:[e:1066..1239] = [t:1066..1239]
;8)sentence:[e:1240..1426] = [t:1240..1426]
;9)sentence:[e:1427..1551] = [t:1427..1551]
;10)sentence:[e:1552..1745] = [t:1552..1745]
;11)sentence:[e:1746..2086] = [t:1746..2086]
;12)section:[e:2090..2134] = [t:2090..2134]

;section 0 Span:0..42
;J Invest Dermatol  1998 Dec;111(6):1227-31
(SEC
  (FRAG (NNP:[0..1] J) (DT:[2..8] Invest) (NNP:[9..17] Dermatol)
        (CD:[19..23] 1998) (.:[24..32] Dec;111-LRB-) (CD:[32..34] 6-RRB-)
        (CD:[34..39] :1227) (HYPH:[39..40] -) (CD:[40..42] 31)))

;sentence 1 Span:47..210
;Identification of activating c-kit mutations in adult-, but not in 
;childhood-onset indolent mastocytosis: a possible explanation for divergent 
;clinical behavior.
;[76..81]:gene-rna:"c-kit"
;[95..101]...[125..152]:malignancy:"adult-"..."onset indolent mastocytosis"
;[115..152]:malignancy:"childhood-onset indolent mastocytosis"
(SENT
  (NP-HLN
    (NP
      (NP (NN:[47..61] Identification))
      (PP (IN:[62..64] of)
        (NP (VBG:[65..75] activating) (NN:[76..81] c-kit)
            (NNS:[82..91] mutations)))
      (PP
        (PP (IN:[92..94] in)
          (NP
            (NML (NN:[95..100] adult) (HYPH:[100..101] -)
              (NML-1 (-NONE-:[101..101] *RNR*)))
            (NML-2 (-NONE-:[101..101] *RNR*))))
        (,:[101..102] ,)
        (CONJP (CC:[103..106] but) (RB:[107..110] not))
        (PP (IN:[111..113] in)
          (NP
            (NML (NN:[115..124] childhood) (HYPH:[124..125] -)
              (NML-1 (-NONE-:[125..125] *RNR*)))
            (NML-2 (-NONE-:[125..125] *RNR*))))
        (NML-1 (NN:[125..130] onset))
        (NML-2 (JJ:[131..139] indolent) (NN:[140..152] mastocytosis))))
    (::[152..153] :)
    (NP
      (NP (DT:[154..155] a) (JJ:[156..164] possible) (NN:[165..176] explanation))
      (PP (IN:[177..180] for)
        (NP (JJ:[181..190] divergent) (JJ:[192..200] clinical)
            (NN:[201..209] behavior))))
    (.:[209..210] .)))

;section 2 Span:214..262
;Buttner C, Henz BM, Welker P, Sepp NT, Grabbe J.
(SEC
  (FRAG (NNP:[214..221] Buttner) (NNP:[222..223] C) (,:[223..224] ,)
        (NNP:[225..229] Henz) (NNP:[230..232] BM) (,:[232..233] ,)
        (NNP:[234..240] Welker) (NNP:[241..242] P) (,:[242..243] ,)
        (NNP:[244..248] Sepp) (NNP:[249..251] NT) (,:[251..252] ,)
        (NNP:[253..259] Grabbe) (NNP:[260..262] J.)))

;section 3 Span:266..339
;Department of Dermatology, Charite, Humboldt University, Berlin, Germany.
(SEC
  (FRAG (NNP:[266..276] Department) (IN:[277..279] of)
        (NNP:[280..291] Dermatology) (,:[291..292] ,) (NNP:[293..300] Charite)
        (,:[300..301] ,) (NNP:[302..310] Humboldt) (NNP:[311..321] University)
        (,:[321..322] ,) (NNP:[323..329] Berlin) (,:[329..330] ,)
        (NNP:[331..338] Germany) (.:[338..339] .)))

;sentence 4 Span:343..715
;Mastocytosis represents a mast cell proliferative disease that generally runs
;a  benign clinical course, with spontaneous remissions mostly by puberty in 
;childhood-onset disease, although rare forms, particularly in adult-onset 
;disease, can be associated with (pre)malignant hematologic disorders and very
; rarely present as mast cell leukemia or malignant mastocytosis.
;[343..355]:malignancy:"Mastocytosis"
;[498..521]:malignancy:"childhood-onset disease"
;[560..580]:malignancy:"adult-onset  disease"
;[670..688]:malignancy:"mast cell leukemia"
;[692..714]:malignancy:"malignant mastocytosis"
(SENT
  (S
    (NP-SBJ (NN:[343..355] Mastocytosis))
    (VP (VBZ:[356..366] represents)
      (NP
        (NP (DT:[367..368] a)
          (NML (NN:[369..373] mast) (NN:[374..378] cell))
          (JJ:[379..392] proliferative) (NN:[393..400] disease))
        (SBAR
          (WHNP-2 (WDT:[401..405] that))
          (S
            (NP-SBJ-2 (-NONE-:[405..405] *T*))
            (ADVP (RB:[406..415] generally))
            (VP (VBZ:[416..420] runs)
              (NP (DT:[421..422] a) (JJ:[424..430] benign)
                  (JJ:[431..439] clinical) (NN:[440..446] course)))))
        (,:[446..447] ,)
        (PP (IN:[448..452] with)
          (NP
            (NP (JJ:[453..464] spontaneous) (NNS:[465..475] remissions))
            (PP
              (ADVP (RB:[476..482] mostly))
              (IN:[483..485] by)
              (NP (NN:[486..493] puberty)))
            (PP (IN:[494..496] in)
              (NP
                (NML (NN:[498..507] childhood) (HYPH:[507..508] -)
                     (NN:[508..513] onset))
                (NN:[514..521] disease))))))
      (,:[521..522] ,)
      (SBAR-ADV (IN:[523..531] although)
        (S
          (NP-SBJ-1 (JJ:[532..536] rare) (NNS:[537..542] forms))
          (,:[542..543] ,)
          (PP
            (ADVP (RB:[544..556] particularly))
            (IN:[557..559] in)
            (NP
              (NML (NN:[560..565] adult) (HYPH:[565..566] -)
                   (NN:[566..571] onset))
              (NN:[573..580] disease)))
          (,:[580..581] ,)
          (VP
            (VP (MD:[582..585] can)
              (VP (VB:[586..588] be)
                (VP (VBN:[589..599] associated)
                  (NP-1 (-NONE-:[599..599] *))
                  (PP-CLR (IN:[600..604] with)
                    (NP (JJ:[605..619] -LRB-pre-RRB-malignant)
                        (JJ:[620..631] hematologic) (NNS:[632..641] disorders))))))
            (CC:[642..645] and)
            (VP
              (ADVP (RB:[646..650] very) (RB:[652..658] rarely))
              (VBP:[659..666] present)
              (PP (IN:[667..669] as)
                (NP
                  (NP
                    (NML (NN:[670..674] mast) (NN:[675..679] cell))
                    (NN:[680..688] leukemia))
                  (CC:[689..691] or)
                  (NP (JJ:[692..701] malignant) (NN:[702..714] mastocytosis)))))))))
    (.:[714..715] .)))

;sentence 5 Span:716..816
;Reasons for this  divergent clinical behavior of childhood- versus
;adult-onset disease are  unknown.
;[765..775]...[789..802]:malignancy:"childhood-"..."onset disease"
;[783..802]:malignancy:"adult-onset disease"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[716..723] Reasons))
      (PP (IN:[724..727] for)
        (NP
          (NP (DT:[728..732] this) (JJ:[734..743] divergent)
              (JJ:[744..752] clinical) (NN:[753..761] behavior))
          (PP (IN:[762..764] of)
            (NP
              (NP
                (NML (NN:[765..774] childhood) (HYPH:[774..775] -)
                  (NML-1 (-NONE-:[775..775] *RNR*)))
                (NML-2 (-NONE-:[775..775] *RNR*)))
              (PP (IN:[776..782] versus)
                (NP
                  (NML (NN:[783..788] adult) (HYPH:[788..789] -)
                    (NML-1 (-NONE-:[789..789] *RNR*)))
                  (NML-2 (-NONE-:[789..789] *RNR*))))
              (NML-1 (NN:[789..794] onset))
              (NML-2 (NN:[795..802] disease)))))))
    (VP (VBP:[803..806] are)
      (ADJP-PRD (JJ:[808..815] unknown)))
    (.:[815..816] .)))

;sentence 6 Span:817..1065
;Recently, two activating mutations in the intracellular domain of the 
;proto-oncogene c-kit, which encodes a tyrosine kinase receptor for the mast
;cell  growth factor stem cell factor, have been detected in the human
;leukemic mast  cell line HMC-1.
;[903..908]:gene-rna:"c-kit"
;[926..950]:gene-protein:"tyrosine kinase receptor"
;[959..1000]:gene-protein:"mast cell  growth factor stem cell factor"
;[1034..1053]:malignancy:"leukemic mast  cell"
(SENT
  (S
    (ADVP-TMP (RB:[817..825] Recently))
    (,:[825..826] ,)
    (NP-SBJ-2
      (NP (CD:[827..830] two) (VBG:[831..841] activating)
          (NNS:[842..851] mutations))
      (PP (IN:[852..854] in)
        (NP
          (NP (DT:[855..858] the) (JJ:[859..872] intracellular)
              (NN:[873..879] domain))
          (PP (IN:[880..882] of)
            (NP
              (NP
                (NP (DT:[883..886] the) (AFX:[888..893] proto)
                    (HYPH:[893..894] -) (NN:[894..902] oncogene))
                (NP (NN:[903..908] c-kit)))
              (,:[908..909] ,)
              (SBAR
                (WHNP-1 (WDT:[910..915] which))
                (S
                  (NP-SBJ-1 (-NONE-:[915..915] *T*))
                  (VP (VBZ:[916..923] encodes)
                    (NP
                      (NP (DT:[924..925] a)
                         (NN:[926..934] tyrosine) (NN:[935..941] kinase)
                         (NN:[942..950] receptor))
                      (PP (IN:[951..954] for)
                        (NP (DT:[955..958] the)
                          
                          (NML
                            (NML (NN:[959..963] mast) (NN:[964..968] cell))
                            (NML (NN:[970..976] growth) (NN:[977..983] factor)))
                          (NML
                            (NML (NN:[984..988] stem) (NN:[989..993] cell))
                            (NN:[994..1000] factor)))))))))))))
    (,:[1000..1001] ,)
    (VP (VBP:[1002..1006] have)
      (VP (VBN:[1007..1011] been)
        (VP (VBN:[1012..1020] detected)
          (NP-2 (-NONE-:[1020..1020] *))
          (PP (IN:[1021..1023] in)
            (NP
              (NML (DT:[1024..1027] the) (JJ:[1028..1033] human)
                 (JJ:[1034..1042] leukemic)
                (NML (NN:[1043..1047] mast) (NN:[1049..1053] cell))
                (NN:[1054..1058] line))
              (NML (NN:[1059..1064] HMC-1)))))))
    (.:[1064..1065] .)))

;sentence 7 Span:1066..1239
;We have therefore studied lesional skin biopsies from patients  with adult-
;and childhood-onset indolent mastocytosis for the presence of these  codon
;560 and 816 mutations.
;[1135..1141]...[1156..1183]:malignancy:"adult-"..."onset indolent
;mastocytosis"
;[1146..1183]:malignancy:"childhood-onset indolent mastocytosis"
;[1211..1220]:variation-location:"codon 560"
;[1211..1216]...[1225..1228]:variation-location:"codon"..."816"
;[1229..1238]:variation-event:"mutations"
(SENT
  (S
    (NP-SBJ (PRP:[1066..1068] We))
    (VP (VBP:[1069..1073] have)
      (ADVP (RB:[1074..1083] therefore))
      (VP (VBN:[1084..1091] studied)
        (NP
          (NP (JJ:[1092..1100] lesional) (NN:[1101..1105] skin)
              (NNS:[1106..1114] biopsies))
          (PP (IN:[1115..1119] from)
            (NP
              (NP (NNS:[1120..1128] patients))
              (PP (IN:[1130..1134] with)
                (NP
                  (NP
                    (NML (NN:[1135..1140] adult) (HYPH:[1140..1141] -)
                      (NML-3 (-NONE-:[1141..1141] *P*)))
                    (NML-4 (-NONE-:[1141..1141] *P*)))
                  (CC:[1142..1145] and)
                  (NP
                    (NML (NN:[1146..1155] childhood) (HYPH:[1155..1156] -)
                      (NML-3 (NN:[1156..1161] onset)))
                    (NML-4 (JJ:[1162..1170] indolent)
                           (NN:[1171..1183] mastocytosis))))))))
        (PP (IN:[1184..1187] for)
          (NP
            (NP (DT:[1188..1191] the) (NN:[1192..1200] presence))
            (PP (IN:[1201..1203] of)
              (NP (DT:[1204..1209] these)
                (NML
                  (NML
                    (NML
                      (NML-2 (NN:[1211..1216] codon))
                      (CD:[1217..1220] 560))
                    (NML-1 (-NONE-:[1220..1220] *P*)))
                  (CC:[1221..1224] and)
                  (NML
                    (NML
                      (NML-2 (-NONE-:[1224..1224] *P*))
                      (CD:[1225..1228] 816))
                    (NML-1 (NNS:[1229..1238] mutations))))))))))
    (.:[1238..1239] .)))

;sentence 8 Span:1240..1426
;C-kit coding DNA sequences were amplified and  analyzed by mutation-specific
;restriction analyses, and mutated polymerase chain  reaction products were
;additionally cloned and sequenced.
;[1240..1245]:gene-rna:"C-kit"
;[1351..1361]:gene-protein:"polymerase"
(SENT
  (S
    (S
      (NP-SBJ-2 (NN:[1240..1245] C-kit) (VBG:[1246..1252] coding)
                (NN:[1253..1256] DNA) (NNS:[1257..1266] sequences))
      (VP (VBD:[1267..1271] were)
        (VP (VBN:[1272..1281] amplified) (CC:[1282..1285] and)
            (VBN:[1287..1295] analyzed)
          (NP-2 (-NONE-:[1295..1295] *))
          (PP-MNR (IN:[1296..1298] by)
            (NP
              (NML (NN:[1299..1307] mutation) (HYPH:[1307..1308] -)
                   (JJ:[1308..1316] specific))
              (NN:[1317..1328] restriction) (NNS:[1329..1337] analyses))))))
    (,:[1337..1338] ,) (CC:[1339..1342] and)
    (S
      (NP-SBJ-1 (VBN:[1343..1350] mutated)
        (NML (NN:[1351..1361] polymerase) (NN:[1362..1367] chain)
             (NN:[1369..1377] reaction))
        (NNS:[1378..1386] products))
      (VP (VBD:[1387..1391] were)
        (ADVP (RB:[1392..1404] additionally))
        (VP (VBN:[1405..1411] cloned) (CC:[1412..1415] and)
            (VBN:[1416..1425] sequenced)
          (NP-1 (-NONE-:[1425..1425] *)))))
    (.:[1425..1426] .)))

;sentence 9 Span:1427..1551
;The codon 816 mutation  was found in all six samples from adult patients, but
;not in any of the 11  specimens from children.
;[1431..1440]:variation-location:"codon 816"
;[1441..1449]:variation-event:"mutation"
(SENT
  (S
    (NP-SBJ-2 (DT:[1427..1430] The)
      (NML (NN:[1431..1436] codon) (CD:[1437..1440] 816))
      (NN:[1441..1449] mutation))
    (VP (VBD:[1451..1454] was)
      (VP
        (VP (VBN:[1455..1460] found)
          (NP-2 (-NONE-:[1460..1460] *))
          (PP=1 (IN:[1461..1463] in)
            (NP
              (NP (DT:[1464..1467] all) (CD:[1468..1471] six)
                  (NNS:[1472..1479] samples))
              (PP (IN:[1480..1484] from)
                (NP (JJ:[1485..1490] adult) (NNS:[1491..1499] patients))))))
        (,:[1499..1500] ,) (CC:[1501..1504] but)
        (VP (RB:[1505..1508] not)
          (PP=1 (IN:[1509..1511] in)
            (NP
              (NP (DT:[1512..1515] any))
              (PP (IN:[1516..1518] of)
                (NP
                  (NP (DT:[1519..1522] the) (CD:[1523..1525] 11)
                      (NNS:[1527..1536] specimens))
                  (PP (IN:[1537..1541] from)
                    (NP (NNS:[1542..1550] children))))))))))
    (.:[1550..1551] .)))

;sentence 10 Span:1552..1745
;In addition, the codon 560 mutation could be  demonstrated for the first time
;in indolent mastocytosis, namely in two of four  specimens from adult
;patients, but not in those from two children.
;[1569..1578]:variation-location:"codon 560"
;[1579..1587]:variation-event:"mutation"
;[1633..1654]:malignancy:"indolent mastocytosis"
(SENT
  (S
    (PP (IN:[1552..1554] In)
      (NP (NN:[1555..1563] addition)))
    (,:[1563..1564] ,)
    (NP-SBJ-1 (DT:[1565..1568] the)
      (NML (NN:[1569..1574] codon) (CD:[1575..1578] 560))
      (NN:[1579..1587] mutation))
    (VP (MD:[1588..1593] could)
      (VP (VB:[1594..1596] be)
        (VP (VBN:[1598..1610] demonstrated)
          (NP-1 (-NONE-:[1610..1610] *))
          (PP (IN:[1611..1614] for)
            (NP (DT:[1615..1618] the) (JJ:[1619..1624] first)
                (NN:[1625..1629] time)))
          (PP (IN:[1630..1632] in)
            (NP (JJ:[1633..1641] indolent) (NN:[1642..1654] mastocytosis)))
          (,:[1654..1655] ,)
          (PP
            (PP
              (ADVP (RB:[1656..1662] namely))
              (IN:[1663..1665] in)
              (NP
                (NP (CD:[1666..1669] two))
                (PP (IN:[1670..1672] of)
                  (NP
                    (NP (CD:[1673..1677] four) (NNS:[1679..1688] specimens))
                    (PP (IN:[1689..1693] from)
                      (NP (JJ:[1694..1699] adult) (NNS:[1700..1708] patients)))))))
            (,:[1708..1709] ,)
            (CONJP (CC:[1710..1713] but) (RB:[1714..1717] not))
            (PP (IN:[1718..1720] in)
              (NP
                (NP (DT:[1721..1726] those))
                (PP (IN:[1727..1731] from)
                  (NP (CD:[1732..1735] two) (NNS:[1736..1744] children)))))))))
    (.:[1744..1745] .)))

;sentence 11 Span:1746..2086
;These data  thus provide a possible explanation for the divergent clinical
;behavior of  adult- versus childhood-onset indolent mastocytosis, with the
;first being  associated with an activating mutation, possibly as part of a
;neoplastic  process, and the latter representing most likely a reactive
;process of an as yet  unknown pathogenesis.
;[1834..1840]...[1858..1885]:malignancy:"adult-"..."onset indolent
;mastocytosis"
;[1848..1885]:malignancy:"childhood-onset indolent mastocytosis"
(SENT
  (S
    (NP-SBJ (DT:[1746..1751] These) (NNS:[1752..1756] data))
    (ADVP (RB:[1758..1762] thus))
    (VP (VBP:[1763..1770] provide)
      (NP
        (NP (DT:[1771..1772] a) (JJ:[1773..1781] possible)
            (NN:[1782..1793] explanation))
        (PP (IN:[1794..1797] for)
          (NP
            (NP (DT:[1798..1801] the) (JJ:[1802..1811] divergent)
                (JJ:[1812..1820] clinical) (NN:[1821..1829] behavior))
            (PP (IN:[1830..1832] of)
              (NP
                (NP
                  (NML (NN:[1834..1839] adult) (HYPH:[1839..1840] -)
                    (NML-2 (-NONE-:[1840..1840] *RNR*)))
                  (NML-3 (-NONE-:[1840..1840] *RNR*)))
                (PP (IN:[1841..1847] versus)
                  (NP
                    (NML (NN:[1848..1857] childhood) (HYPH:[1857..1858] -)
                      (NML-2 (-NONE-:[1858..1858] *RNR*)))
                    (NML-3 (-NONE-:[1858..1858] *RNR*))))
                (NML-2 (NN:[1858..1863] onset))
                (NML-3 (JJ:[1864..1872] indolent) (NN:[1873..1885] mastocytosis)))))))
      (,:[1885..1886] ,)
      (PP (IN:[1887..1891] with)
        (S-NOM
          (S
            (NP-SBJ-1 (DT:[1892..1895] the) (JJ:[1896..1901] first))
            (VP (VBG:[1902..1907] being)
              (VP (VBN:[1909..1919] associated)
                (NP-1 (-NONE-:[1919..1919] *))
                (PP-CLR (IN:[1920..1924] with)
                  (NP (DT:[1925..1927] an) (VBG:[1928..1938] activating)
                      (NN:[1939..1947] mutation)))
                (,:[1947..1948] ,)
                (PP
                  (ADVP (RB:[1949..1957] possibly))
                  (IN:[1958..1960] as)
                  (NP
                    (NP (NN:[1961..1965] part))
                    (PP (IN:[1966..1968] of)
                      (NP (DT:[1969..1970] a) (JJ:[1971..1981] neoplastic)
                          (NN:[1983..1990] process))))))))
          (,:[1990..1991] ,) (CC:[1992..1995] and)
          (S
            (NP-SBJ (DT:[1996..1999] the) (JJ:[2000..2006] latter))
            (VP (VBG:[2007..2019] representing)
              (ADVP (RBS:[2020..2024] most) (RB:[2025..2031] likely))
              (NP
                (NP (DT:[2032..2033] a) (JJ:[2034..2042] reactive)
                    (NN:[2043..2050] process))
                (PP (IN:[2051..2053] of)
                  (NP (DT:[2054..2056] an)
                    (ADJP
                      (ADVP (RB:[2057..2059] as) (RB:[2060..2063] yet))
                      (JJ:[2065..2072] unknown))
                    (NN:[2073..2085] pathogenesis)))))))))
    (.:[2085..2086] .)))

;section 12 Span:2090..2134
;PMID: 9856847 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2090..2094] PMID) (::[2094..2095] :) (CD:[2096..2103] 9856847)
        (IN:[2104..2105] -LSB-) (NNP:[2105..2111] PubMed) (HYPH:[2112..2113] -)
        (JJ:[2114..2121] indexed) (IN:[2122..2125] for)
        (NNP:[2126..2134] MEDLINE-RSB-)))
